Evidence map›Paper›PMID 39880699›Full record

ArticleThe journal of prevention of Alzheimer's disease2025

MemScreen: A smartphone application for detection of mild cognitive impairment: A validation study: Smartphone App for MCI Detection.

Julien Dumurgier, Claire Paquet, Jacques Hugon, Vincent Planche, Sinead Gaubert, Stéphane Epelbaum, Stéphanie Bombois, Marc Teichmann, Richard Levy, Estelle Baudouin and 5 more

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of prevention of Alzheimer's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Julien DumurgierUniversité Paris-Cité, Cognitive Neurology Center, GHU APHP Nord Lariboisière Fernand-Widal Hospital, 200 rue du Faubourg Saint Denis, 75010 Paris, France; Université Paris Cité, INSERM U1153, Centre of Research in Epidemiology and Statistics, Team Epidemiology of Ageing and Neurodegenerative Diseases, 10 avenue de Verdun, 75010 Paris, France. Electronic address: julien.dumurgier@aphp.fr.
Claire PaquetUniversité Paris-Cité, Cognitive Neurology Center, GHU APHP Nord Lariboisière Fernand-Widal Hospital, 200 rue du Faubourg Saint Denis, 75010 Paris, France; Université Paris Cité, INSERM U1144, Therapeutic Optimization in Neuropsychopharmacology, 2 rue Ambroise Paré, 7510 Paris, France.
Jacques HugonUniversité Paris-Cité, Cognitive Neurology Center, GHU APHP Nord Lariboisière Fernand-Widal Hospital, 200 rue du Faubourg Saint Denis, 75010 Paris, France; Université Paris Cité, INSERM U1144, Therapeutic Optimization in Neuropsychopharmacology, 2 rue Ambroise Paré, 7510 Paris, France.
Vincent PlancheInstitut des Maladies Neurodégénératives, Bordeaux University, CNRS, UMR 5293, 146 Rue Léo Saignat, 33000 Bordeaux, Bordeaux, France.
Sinead GaubertUniversité Paris-Cité, Cognitive Neurology Center, GHU APHP Nord Lariboisière Fernand-Widal Hospital, 200 rue du Faubourg Saint Denis, 75010 Paris, France.
Stéphane EpelbaumSorbonne Université, Institute of Memory and Alzheimer's Disease, Groupe Hospitalier Pitié-Salpêtrière, AP-HP, 47 boulevard de l'Hôpital, 75010 Paris, France.
Stéphanie BomboisSorbonne Université, Institute of Memory and Alzheimer's Disease, Groupe Hospitalier Pitié-Salpêtrière, AP-HP, 47 boulevard de l'Hôpital, 75010 Paris, France.
Marc TeichmannSorbonne Université, Institute of Memory and Alzheimer's Disease, Groupe Hospitalier Pitié-Salpêtrière, AP-HP, 47 boulevard de l'Hôpital, 75010 Paris, France.
Richard LevySorbonne Université, Institute of Memory and Alzheimer's Disease, Groupe Hospitalier Pitié-Salpêtrière, AP-HP, 47 boulevard de l'Hôpital, 75010 Paris, France.
Estelle BaudouinGroupement Hospitalier Portes de Provence, route de Sauzet. 26200 Montélimar, France.
Agathe VrillonUniversité Paris-Cité, Cognitive Neurology Center, GHU APHP Nord Lariboisière Fernand-Widal Hospital, 200 rue du Faubourg Saint Denis, 75010 Paris, France; Université Paris Cité, INSERM U1144, Therapeutic Optimization in Neuropsychopharmacology, 2 rue Ambroise Paré, 7510 Paris, France.
Claire HourrègueUniversité Paris-Cité, Cognitive Neurology Center, GHU APHP Nord Lariboisière Fernand-Widal Hospital, 200 rue du Faubourg Saint Denis, 75010 Paris, France.
Emmanuel CognatUniversité Paris-Cité, Cognitive Neurology Center, GHU APHP Nord Lariboisière Fernand-Widal Hospital, 200 rue du Faubourg Saint Denis, 75010 Paris, France; Université Paris Cité, INSERM U1144, Therapeutic Optimization in Neuropsychopharmacology, 2 rue Ambroise Paré, 7510 Paris, France.
Séverine SabiaUniversité Paris Cité, INSERM U1153, Centre of Research in Epidemiology and Statistics, Team Epidemiology of Ageing and Neurodegenerative Diseases, 10 avenue de Verdun, 75010 Paris, France; Faculty of Brain Sciences, University College London, 38-50 Bidborough Street, WC1H 9BT London, UK.
Archana Singh-ManouxUniversité Paris Cité, INSERM U1153, Centre of Research in Epidemiology and Statistics, Team Epidemiology of Ageing and Neurodegenerative Diseases, 10 avenue de Verdun, 75010 Paris, France; Faculty of Brain Sciences, University College London, 38-50 Bidborough Street, WC1H 9BT London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesPrimary care is often the first point of contact for patients with cognitive complaints, making initial cognitive screening an essential step to avoid delays in diagnosing Alzheimer's disease (AD) at an early stage. We developed MemScreen, a self-administered smartphone application that assesses overall cognition and verbal memory, and evaluated its ability to detect mild cognitive impairment (MCI) in both general and clinical populations.

methodsWe conducted two validation cohort studies: (1) UK-based Whitehall II cohort study (13th wave, 2018-2022) involving a general population (MCI defined by poor performance on a global cognitive score), and (2) five French memory clinics involving patients without dementia (amnestic MCI defined by the Free and Cued Selective Reminding Test). MemScreen, MMSE, and TMT-A effectiveness was assessed using Area Under the Curve (AUC) values from unadjusted and adjusted logistic regression models.

resultsIn Whitehall II (n = 2118, mean age 75.9 years, 23.9 % women, 14.5 % MCI), median MemScreen completion time was 4 min 18 s. MemScreen had the highest AUC (0.87; 95 % CI: 0.82-0.89) for distinguishing MCI, outperforming MMSE (AUC = 0.79; 0.76-0.82; p = 0.018) and TMT-A (AUC = 0.77; 0.74-0.80; p = 0.023). MemScreen sensitivity and specificity were 78.6 % and 78.7 %, respectively. In memory clinics (n = 303, mean age 70.5 years, 53 % women, 46.9 % amnestic MCI), median completion time was 5 min 17 s. MemScreen showed superior performance (AUC = 0.87; 0.83-0.91) compared to MMSE (AUC = 0.72; 0.67-0.78; p < 0.001) and TMT-A (AUC = 0.63; 0.56-0.69; p < 0.001), with 93.0 % sensitivity and 54.0 % specificity for amnestic MCI. DISCUSSION: MemScreen outperformed traditional tests in identifying MCI in both general and clinical populations. Its self-administration and short completion time suggest potential as an effective screening tool to optimize memory clinic referrals for AD diagnosis and treatment.

Indexed as

Cognitive DysfunctionMobile ApplicationsSmartphoneAgedAged, 80 and overCohort StudiesFemaleHumansMaleMental Status and Dementia TestsNeuropsychological TestsCognitive screeningDigital health toolMemScreenMild cognitive impairmentSmartphone applicationValidation study

Identifiers

PMID39880699
PMCPMC12183962

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.